| Literature DB >> 29681456 |
Charissa Kim1, Ruli Gao2, Emi Sei2, Rachel Brandt2, Johan Hartman3, Thomas Hatschek3, Nicola Crosetto4, Theodoros Foukakis5, Nicholas E Navin6.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations. To investigate this question, we applied single-cell DNA and RNA sequencing in addition to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC). Deep-exome sequencing identified 10 patients in which NAC led to clonal extinction and 10 patients in which clones persisted after treatment. In 8 patients, we performed a more detailed study using single-cell DNA sequencing to analyze 900 cells and single-cell RNA sequencing to analyze 6,862 cells. Our data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.Entities:
Keywords: breast cancer genomics; cancer aneuploidy; chemotherapy; copy-number evolution; intratumor heterogeneity; single-cell sequencing; therapy resistance; triple-negative breast cancer; tumor evolution
Mesh:
Substances:
Year: 2018 PMID: 29681456 PMCID: PMC6132060 DOI: 10.1016/j.cell.2018.03.041
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582